Abstract Background and Aims This study aimed to compare real-world clinical effectiveness
and safety of vedolizumab, an α4β7-integrin inhibitor, and anti-tumour necrosis factor-α [anti …

Introduction: Selective blockade of the integrins and mucosal adhesion molecules is a
promising therapeutic strategy for ulcerative colitis (UC). Vedolizumab (VDZ), a humanized …

Introduction: The management of patients with ulcerative colitis (UC) has evolved over the
past few decades. While aminosalicylates remain the mainstay of induction and …

Abstract Background and Objectives The safety of inflammatory bowel disease medications
during lactation is of significant relevance to women of childbearing potential. Available data …

Biological therapies, especially blocking tumor necrosis factor-α (TNFα) agents have
radically changed the therapeutic approach and disease course of pediatric inflammatory …

JC polyomavirus (JCPyV) is a human polyomavirus that was first identified in 1971 as the
cause of progressive multifocal leukoencephalopathy (PML) in the brain of John …

Crohn's disease (CD) and ulcerative colitis (UC) are chronic, immune-mediated diseases of
the gastrointestinal (GI) tract. Their etiology is complex and involves immune (eg, cytokines) …

Background Despite research, there are still controversial areas in the management of
Crohn's disease (CD). Objective To establish practical recommendations on using anti …

Inflammatory bowel disease (IBD), which comprises ulcerative colitis and Crohn's disease, is
an immune-mediated, chronic-relapsing, disabling disorder which is associated with …

Leukocyte trafficking is critical in most immunological processes, ranging from the
establishment of immunological tissue homeostasis to aberrant immune responses leading …